Evidence from both laboratory [2, 3] and epidemiologic studies supports that prolactin is involved in mammary tumorigenesis [4, 5], with stronger associations for postmenopausal breast cancer that led to improvements in risk prediction models [6–8]. Here, PRL is linked to breast carcinoma.